Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced...

Area of Science:

• Biomaterials Science
• Orthopedics
• Immunology

Background:

• Prosthesis loosening is a major complication of joint arthroplasty, often caused by wear particles stimulating osteoclast activity.
• Osteolysis, or bone loss around the implant, is driven by osteoclastogenesis, making it a key target for preventing loosening.
• Inhibiting osteoclastogenesis presents a viable strategy to manage periprosthetic osteolysis and improve implant longevity.

Purpose of the Study:

• To investigate the mechanism by which rhoifolin affects osteoclastogenesis.
• To evaluate rhoifolin's efficacy in mitigating titanium particle-induced osteolysis in vitro and in vivo.
• To explore rhoifolin's potential as a therapeutic agent for aseptic prosthesis loosening.

Main Methods:

• In vitro assessment of rhoifolin's effects on osteoclast differentiation, resorption, and gene expression.
• Western blot analysis to examine the impact of rhoifolin on key signaling pathways (NF-κB, MAPK) and transcription factors (NFATc1, c-Fos).
• In vivo study using a mouse calvarial model to assess rhoifolin's effect on bone loss induced by titanium particles.

Main Results:

• Rhoifolin significantly suppressed receptor activator of nuclear factor-κB ligand-stimulated osteoclastogenesis, hydroxyapatite resorption, and F-actin formation.
• Rhoifolin attenuated the NF-κB and MAPK signaling pathways, reducing the expression of NFATc1 and c-Fos.
• In vivo, rhoifolin decreased osteoclast numbers and protected against titanium particle-induced calvarial bone loss in mice.

Conclusions:

• Rhoifolin effectively inhibits osteoclastogenesis and osteolysis stimulated by wear particles.
• Rhoifolin demonstrates therapeutic potential for managing aseptic prosthesis loosening.
• Further research into rhoifolin as a treatment for implant-related bone loss is warranted.